Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients. - OpacWWW

Szczegóły
Abstrakt

Tytuł:: Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.
Autorzy:: Ono K; Department of Joint Surgery, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Ohashi S; Department of Orthopaedic Surgery, Sagamihara Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara-shi, Sagamihara, Kanagawa, 252-0315, Japan. .
Oka H; Department of Medical Research and Management for Musculoskeletal Pain, Faculty of Medicine, 22nd Century Medical and Research Center, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Kadono Y; Department of Orthopaedic Surgery, Saitama Medical University Hospital, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama, 350-0495, Japan.
Yasui T; Department of Orthopaedic Surgery, Teikyo University Mizonokuchi Hospital, 5-1-1 Futago, Takatsu-ku, Kawasaki-shi, Kawasaki, Kanagawa, 213-8507, Japan.
Matsumoto T; Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Omata Y; Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Tanaka S; Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Źródło:: Journal of bone and mineral metabolism [J Bone Miner Metab] 2021 Mar; Vol. 39 (2), pp. 270-277. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji:: Journal Article; Observational Study
Język:: English
Imprint Name(s):: Original Publication: Tokyo : Japanese Society of Bone and Mineral Metabolism, [1988-
MeSH Terms:: Finite Element Analysis*
Arthritis, Rheumatoid/*drug therapy
Teriparatide/*therapeutic use
Absorptiometry, Photon ; Aged ; Area Under Curve ; Arthritis, Rheumatoid/blood ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/physiopathology ; Biomarkers/blood ; Bone Density/drug effects ; Bone Density Conservation Agents/pharmacology ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling/drug effects ; Drug Administration Schedule ; Female ; Humans ; Logistic Models ; Male ; Teriparatide/pharmacology
References:: Hoes JN, Bultink EI, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16:559–571. (PMID: 10.1517/14656566.2015.997709)
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112. (PMID: 10.1002/art.22117)
Omata Y, Hagiwara F, Nishino J, Matsudaira K, Kadono Y et al (2014) Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. J Bone Miner Metab 32:725–731. (PMID: 10.1007/s00774-013-0552-8)
Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y et al (2015) Ten-year incidence of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int 26:961–968. (PMID: 10.1007/s00198-014-2911-2)
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. J Engl J Med 344:1434–1441. (PMID: 10.1056/NEJM200105103441904)
Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trail. Arthritis Rheum 60:3346–3355. (PMID: 10.1002/art.24879)
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916. (PMID: 10.1056/NEJMra067395)
Jiang Y, Zhao JJ, Mitlak BH, Wanq O, Genant HK et al (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941. (PMID: 10.1359/jbmr.2003.18.11.1932)
Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502. (PMID: 10.1016/j.bone.2010.05.022)
Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M et al (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan fracture Observational Study (JFOS). Curr Med Res Opin 33:2049–2056. (PMID: 10.1080/03007995.2017.1354826)
Link TM, Kazakia G (2020) Update on imaging-based measurement of bone mineral density and quality. Curr Rheumatol Rep 22:13. https://doi.org/10.1007/s11926-020-00892-w. (PMID: 10.1007/s11926-020-00892-w32270332)
Solomon DH, Kremer J, Cutis JR, Hochberq MC, Reed G et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925. (PMID: 10.1136/ard.2009.122226)
NIH consensus development panel on osteoporosis prevention (2001) Diagnosis and therapy. Osteoporosis prevention diagnosis and therapy. JAMA 285:785–796. (PMID: 10.1001/jama.285.6.785)
Dall’Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563–572. (PMID: 10.1007/s00198-011-1568-3)
Imai K, Ohnishi I, Bessho M, Nakamura K (2006) Nonlinear finite element model predicts vertebral bone strength and fracture site. Spine 31:1789–1794. (PMID: 10.1097/01.brs.0000225993.57349.df)
Bessho M, Ohnishi I, Matsuyama J, Matsumoto T, Imai K et al (2007) Prediction of strength and strain of the proximal femur by a CT-based finite element method. J Biomech 40:1745–1753. (PMID: 10.1016/j.jbiomech.2006.08.003)
Kaneko M, Ohnishi I, Matsumoto T, Ohashi S, Bessho M et al (2016) Prediction of proximal femur strength by a quantitative computed tomography-based finite element method- Creation of predicted strength data of the proximal femur according to age range in a normal population. Modern Rheumatol 26:151–155. (PMID: 10.3109/14397595.2015.1046220)
Imai K, Ohnishi T, Matsumoto T, Yamamoto S, Nakamura K (2009) Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20:801–810. (PMID: 10.1007/s00198-008-0750-8)
Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y et al (2008) Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. Arthritis Rheum 58:3340–3349. (PMID: 10.1002/art.23988)
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. (PMID: 10.1002/art.1780310302)
Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:798–803. (PMID: 10.1016/j.bone.2010.12.006)
Gallagher JC, Rosen CJ, Chen P, Marcus R (2006) Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268–1275. (PMID: 10.1016/j.bone.2006.06.007)
Gluer CC (1999) Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14:1952–1962. (PMID: 10.1359/jbmr.1999.14.11.1952)
Hair JF, Anderson RE, Tatham RL, Black WC (1998) Multivariate data analysis with readings, 5th edn. Prentice-Hall, Englewood Cliffs.
Hosmer DW, Lemeshow S (2000) Assessing the fit of the model. In: Hosmer DW, Lemshow S (eds) Applied logistic regression, 2nd edn. Wiley, New York, pp 143–202. (PMID: 10.1002/0471722146)
Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH et al (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165–170. (PMID: 10.1016/j.bone.2011.10.002)
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrenrons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600. (PMID: 10.1359/jbmr.080506)
Ebina K, Hashimoto J, Shi K, Kashii M, Hisao M et al (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 25:2755–5765. (PMID: 10.1007/s00198-014-2819-x)
Ono K, Ohashi S, Oka H, Kadono Y, Yasui T et al (2016) The impact of joint disease on the Modified Health Assessment Questionnaire scores in rheumatoid arthritis patients: a cross-sectional study using the national database of rheumatic diseases by iR-net in Japan. Mod Rheumatol 26:529–533. (PMID: 10.3109/14397595.2015.1106640)
Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062. (PMID: 10.1210/jc.2010-0720)
Contributed Indexing:: Keywords: Daily teriparatide; Finite-element analysis; N-terminal type I collagen propeptide; Osteoporosis; Rheumatoid arthritis
Substance Nomenclature:: 0 (Biomarkers)
0 (Bone Density Conservation Agents)
10T9CSU89I (Teriparatide)
Entry Date(s):: Date Created: 20200905 Date Completed: 20210408 Latest Revision: 20210408
Update Code:: 20240104
DOI:: 10.1007/s00774-020-01146-6
PMID:: 32886175
: Czasopismo naukowe

Full Text Finder

Introduction: The objective of this study was to quantitatively evaluate the effects of daily teriparatide on rheumatoid arthritis patients using predicted bone strength (PBS) assessed by quantitative computed tomography-based finite-element analysis (QCT/FEA) and using bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA), and to prospectively investigate clinical determinants associated with PBS and BMD increases.
Materials and Methods: Participants comprised 39 patients (mean age, 69 years; disease activity score assessing 28 joints with CRP, 3.0; previous vertebral fractures, 82%) enrolled in this study. BMD by DXA and PBS by QCT/FEA of lumbar spine (LS) and proximal femur were measured at baseline, and after 6 and 12 months. In the groups showing increases in these values, variables that may have affected these increases were evaluated using univariate logistic regression analysis.
Results: Daily teriparatide treatment significantly increased not only LS BMD, but also LS PBS in RA patients with osteoporosis after both 6 and 12 months of treatment. Increases in N-terminal type I procollagen propeptide (PINP) at 1 and 3 months were significantly associated with increased LS PBS at 12 months according to univariate logistic regression analysis. The threshold value for increased PINP at 1 month for increased PBS at 12 months was 75 µg/L.
Conclusions: Increased LS PBS at 12 months was predicted by increased PINP at 1 month from baseline.

Informacja

Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.